The Board of Directors of Eterna Plc has appointed Mr Olumide Adeosun as the new Managing Director/Chief Executive Officer of Eterna Plc. According to a statement issued on Thursday by the Company ...
Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback